These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23297711)

  • 21. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
    Viberti G; Wheeldon NM;
    Circulation; 2002 Aug; 106(6):672-8. PubMed ID: 12163426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
    Yamamoto E; Kataoka K; Shintaku H; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2569-75. PubMed ID: 17932313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.
    Hirooka Y; Kimura Y; Sagara Y; Ito K; Sunagawa K
    Clin Exp Hypertens; 2008 Apr; 30(3):267-76. PubMed ID: 18425706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients.
    Ohta M; Tajiri Y; Yamato H; Ikeda M
    Clin Exp Hypertens; 2012; 34(7):523-9. PubMed ID: 22559159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
    Epstein M; Hollenberg NK
    Am J Hypertens; 2004 Jul; 17(7):638-9; author reply 639-40. PubMed ID: 15233985
    [No Abstract]   [Full Text] [Related]  

  • 29. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria.
    Smith DG; Nguyen AB; Peak CN; Frech FH
    J Manag Care Pharm; 2004; 10(1):26-32. PubMed ID: 14720103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A
    Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria.
    Peng T; Hu Z; Xia Q; Jiang B; Li X; Yang X
    Arzneimittelforschung; 2009; 59(12):647-50. PubMed ID: 20108651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
    Kjeldsen SE; Julius S; Mancia G; McInnes GT; Hua T; Weber MA; Coca A; Ekman S; Girerd X; Jamerson K; Larochelle P; MacDonald TM; Schmieder RE; Schork MA; Stolt P; Viskoper R; Widimský J; Zanchetti A;
    J Hypertens; 2006 Jul; 24(7):1405-12. PubMed ID: 16794491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].
    Krzesinski JM; Scheen AJ
    Rev Med Liege; 2007 Nov; 62(11):688-94. PubMed ID: 18217647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Yilmaz MI; Sonmez A; Caglar K; Celik T; Yenicesu M; Eyileten T; Acikel C; Oguz Y; Yavuz I; Vural A
    Nephrology (Carlton); 2007 Apr; 12(2):147-53. PubMed ID: 17371337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation?
    Ay SA; Karaman M; Cakar M; Balta S; Arslan E; Bulucu F; Demirbas S; Celik T; Naharci MI; Demirkol S; Kurt O; Bozoglu E
    Ren Fail; 2013; 35(5):691-6. PubMed ID: 23560469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
    Cai J; Huang Z; Yang G; Cheng K; Ye Q; Ming Y; Zuo X; Zhou P; Yuan H
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):401-9. PubMed ID: 22149319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
    Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
    Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.
    Matsushita K; Muramatsu T; Kondo T; Maeda K; Shintani S; Murohara T;
    J Cardiol; 2010 Jul; 56(1):111-7. PubMed ID: 20409690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.